Antitumor Activity of the Novel Human Cytokine AIMP1 in an in vivo Tumor Model

  • Lee, Yeon-Sook (Division of Life Sciences, and Graduate School of Biotechnology, Korea University) ;
  • Han, Jung Min (Imagene Co. Ltd. Biotechnology Incubation Center, Seoul National University) ;
  • Kang, Taehee (Imagene Co. Ltd. Biotechnology Incubation Center, Seoul National University) ;
  • Park, Young In (Division of Life Sciences, and Graduate School of Biotechnology, Korea University) ;
  • Kim, Hwan Mook (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) ;
  • Kim, Sunghoon (National Creative Research Initiatives Center for ARS Network, College of Pharmacy Seoul National University)
  • Received : 2005.10.15
  • Accepted : 2006.02.20
  • Published : 2006.04.30

Abstract

Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.

Keywords

AIMP1;Angiogenesis;Anticancer;EMAP II;p43;Tumor

References

  1. Chang, S. Y., Park, S. G., Kim, S., and Kang, C. Y. (2002) Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase. Its functional implication in endothelial cell proliferation. J. Biol. Chem. 277, 8388–8394 https://doi.org/10.1074/jbc.M108792200
  2. Gervaz, P. and Fontolliet, C. (1998) Therapeutic potential of the anti-angiogenesis drug TNP-470. Int. J. Exp. Pathol. 79, 359-362 https://doi.org/10.1046/j.1365-2613.1998.00087.x
  3. Kao, J., Houck, K., Fan, Y., Haehnel, I., Libutti, S. K., et al. (1994) Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J. Biol. Chem. 269, 25106-25119
  4. Kato, T., Sato, K., Kakinuma, H., and Matsuda, Y. (1994) Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res. 54, 5143-5147
  5. Ko, Y. G., Park, H., Kim, T., Lee, J. W., Park, S. G., et al. (2001) A cofactor of tRNA synthetase, p43, is secreted to upregulate proinflammatory genes. J. Biol. Chem. 276, 23028-23033 https://doi.org/10.1074/jbc.M101544200
  6. Hayes, A. J., Li, L. Y., and Lippman, M. E. (1999) Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. BMJ 318, 853-856 https://doi.org/10.1136/bmj.318.7187.853
  7. Park, S. G., Shin, H., Shin, Y. K., Lee, Y., Choi, E. C., et al. (2005) The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. Am. J. Pathol. 166, 387-398 https://doi.org/10.1016/S0002-9440(10)62262-6
  8. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257–265
  9. Schwarz, M. A., Kandel, J., Brett, J., Li, J., Hayward, J., et al. (1999) Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J. Exp. Med. 190, 341-354 https://doi.org/10.1084/jem.190.3.341
  10. Folkman, J. (2003) Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643-651 https://doi.org/10.2174/1566524033479465
  11. Moser, T. L., Kenan, D. J., Ashley, T. A., Roy, J. A., Goodman, M. D., et al. (2001) Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc. Natl. Acad. Sci. USA 98, 6656-6661
  12. Quevillon, S., Agou, F., Robinson, J. C., and Mirande M. (1997) The p43 component of the mammalian multi-synthetase complex is likely to be the precursor of the endothelial monocyte-activating polypeptide II cytokine. J. Biol. Chem. 272, 32573–32579 https://doi.org/10.1074/jbc.272.51.32573
  13. O'Reilly, M. S. (2002) The combination of antiangiogenic therapy with other modalities. Cancer J. 8 (Suppl. 1), S89-99
  14. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (6 Suppl. 16), 15-18 https://doi.org/10.1053/sonc.2002.37263
  15. Moser, T. L., Stack, M. S., Asplin, I., Enghild, J. J., Hojrup, P., et al. (1999) Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 96, 2811–2816
  16. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., and Fidler, I. J. (1999) Interferon-a-mediated down-regulation of angiogenesis- related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726–2734
  17. Ye, D., Mendelsohn, J., and Fan, Z. (1999) Augmentation of a humanized anti-HER2 Mab 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor Mab C225. Oncogene 18, 731-738 https://doi.org/10.1038/sj.onc.1202319
  18. Park, S. G., Kang, Y. S., Ahn, Y. H., Lee, S. H., Kim, K. R., et al. (2002) Dose-dependent biphasic activity of tRNA synthetaseassociating factor, p43, in angiogenesis. J. Biol. Chem. 277, 45243-45248 https://doi.org/10.1074/jbc.M207934200
  19. Inoue, K., Slaton, J. W., Davis, D. W., Hicklin, D. J., McConkey, D. J., et al. (2000) Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res. 6, 2635-2643